CDC’s ACIP Recommends Adding Shingrix to the Adult Vaccination Schedule

The CDC’s Advisory Committee on Immunization Practices (ACIP) voted to include the new recombinant, adjuvanted zoster vaccine (Shingrix, GlaxoSmithKline) in the adult vaccination recommendations for the prevention of shingles (herpes zoster). In the Phase III trial that the drug’s recent FDA approval was based on, Shingrix was shown to reduce the overall incidence of postherpetic neuralgia, a form of chronic nerve pain and the most common complication associated with shingles.